SDGR

22.93012.95%
RF

Ramy Farid

CEO, President & Director

Dr. Ramy Farid, Ph.D. is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He serves as the President of Schrödinger, Inc. since January 2008 and has been its Chief Executive Officer since January 2, 2017. He had been an Independent Director of Structure Therapeutics Inc. (formerly known as ShouTi, Inc.) since April 2019 until 2024. Dr. Farid served as Director of Morphic Holding, Inc. from June 2016 until June 10, 2019. Dr. Farid Co-Founded Nimbus Therapeutics, Inc. in 2009 and served as its President. Dr. Farid served as Senior Vice President of Schr'dinger, LLC from January 2005 to December 2007, Vice President of scientific development and product management from January 2003 to December 2004 and product Manager from January 2002 to December 2002. Dr. Farid joined Schr'dinger in 2002. He served as a Director of Nimbus Therapeutics, Inc. He serves as Director at Morphic Rock Therapeutic, Inc. He has been Director of Schr'dinger, Inc. since December 2012. He was an Assistant Professor in the Chemistry Department of Rutgers University. His research at Rutgers focused on computational protein design, design of highly stable variants of native proteins and construction of synthetic hemoproteins, hydrolytic enzymes and protein-based solar energy conversion devices. He serves as Director of Ajax Therapeutics, Inc. He was a National Institutes of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. He received his PhD in Chemistry from California Institute of Technology in 1991 and B.S. in Chemistry from the University of Rochester.

Positions